Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

B, Weide; A, Martens; JC, Hassel; C, Berking; MA, Postow; K, Bisschop; E, Simeone; J, Mangana; B, Schilling; Giacomo AM, Di; N, Brenner; K, Kähler; L, Heinzerling; R, Gutzmer; A, Bender; C, Gebhardt; E, Romano; F, Meier; P, Martus; M, Maio; C, Blank; D, Schadendorf; R, Dummer; PA, Ascierto; G, Hospers; C, Garbe; JD, Wolchok

doi:10.1158/1078-0432.ccr-16-0127

Public

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

Shared by NobleBlocks on May 16, 2016 • 12:00 AM UTC

Authors:

Weide B

Martens A

Hassel JC

Abstract

Purpose Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients.Experimental design Se...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!